PresentationPresentation A Phase 2 Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) PDF (1.44 MB) Read MorePresentation Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Children with Relapsed or Refractory Leukemia PDF (779.48 KB) Read MorePresentation Targeting nuclear export for triple-negative breast cancer therapy PDF (1.12 MB) Read MorePresentation Targeting nuclear transport pathways to overcome endocrine resistance and recurrence PDF (1,001.43 KB) Read MorePresentation Cell cycle specifi c eff ects and associated DNA damage of selective inhibitors of nuclear export (SINE) PDF (2.15 MB) Read MorePresentation Selective inhibition of nuclear export in patients with neuroblastoma at high risk for treatment failure PDF (1.18 MB) Read MorePresentation Dual inhibition of NAMPT and PAK4 by KPT-9274 attenuates kidney cancer growth PDF (1.27 MB) Read MorePresentation Nuclear-Export of PU.1 with Mutated NPM1 Impedes Terminal Monocytic Differentiation of Acute Myeloid Leukemia Cells PDF (1.39 MB) Read MorePresentation Selinexor, a Selective Inhibitor of Nuclear Export (SINE), Enhances the In Vivo Efficacy of Checkpoint Blockade with Antibodies Targeting CTLA4 or PD-1/PD-L1 in Melanoma PDF (1.68 MB) Read MorePresentation Co-Administration of Nicotinic Acid (NA) Enhances the Therapeutic Index of KPT-9274 in Cancer Cells PDF (1.84 MB) Read More Previous 1 … 4 5 6 7 8 … 15 Next